AVGR vs. PSTV, PAVM, VVOS, GCTK, NURO, AEMD, STSS, INBS, TMDIF, and XLYO
Should you be buying Avinger stock or one of its competitors? The main competitors of Avinger include Plus Therapeutics (PSTV), PAVmed (PAVM), Vivos Therapeutics (VVOS), GlucoTrack (GCTK), NeuroMetrix (NURO), Aethlon Medical (AEMD), Sharps Technology (STSS), Intelligent Bio Solutions (INBS), Titan Medical (TMDIF), and Xylo Technologies (XLYO). These companies are all part of the "surgical & medical instruments" industry.
Avinger (NASDAQ:AVGR) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.
Avinger received 330 more outperform votes than Plus Therapeutics when rated by MarketBeat users. However, 60.58% of users gave Plus Therapeutics an outperform vote while only 58.83% of users gave Avinger an outperform vote.
Avinger currently has a consensus price target of $5.00, suggesting a potential upside of 252.11%. Plus Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 321.05%. Given Plus Therapeutics' higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Avinger.
Plus Therapeutics has a net margin of -193.49% compared to Avinger's net margin of -251.78%. Avinger's return on equity of 0.00% beat Plus Therapeutics' return on equity.
Avinger has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
In the previous week, Avinger and Avinger both had 3 articles in the media. Avinger's average media sentiment score of 0.96 beat Plus Therapeutics' score of 0.62 indicating that Avinger is being referred to more favorably in the media.
18.3% of Avinger shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 11.4% of Avinger shares are held by company insiders. Comparatively, 2.3% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Plus Therapeutics has lower revenue, but higher earnings than Avinger. Plus Therapeutics is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.
Summary
Avinger beats Plus Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Avinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
